Kite Pharma CAR-T Cancer Therapy Shows Strong, Durable Effect in Lymphoma Patients – TheStreet.com
TheStreet.com |
Kite Pharma CAR–T Cancer Therapy Shows Strong, Durable Effect in Lymphoma Patients
TheStreet.com Kite Pharma's (KITE) disclosed Tuesday six-month results from a pivotal study of its CAR–T therapy in patients with aggressive lymphomas that showed only a slight degradation in response rates and no new safety concerns compared to results previously … Kite's CAR–T cancer therapy shows strong results as company races to win FDA approval Kite Pharma's cancer drug clears main goal in study Kite Pharma (KITE) Reports Positive Topline Data on Axicabtagene Ciloleucel from First Pivotal CAR–T Trial in … |
